ASH 2023 | A research update in Richter’s transformation from ASH 2023
Tanya Siddiqi, MD, City of Hope, Duarte, CA, gives a brief update on research into Richter’s transformation (RT), a challenging complication of chronic lymphocytic leukemia (CLL). Dr Siddiqi highlights promising data from the CLL-RT1 trial (NCT04271956), showcasing the efficacy of tislelizumab, a PD1 inhibitor, combined with zanubrutinib in the treatment of RT. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Juno therapeutics, AbbVie, Kite Pharma, Celgene, BeiGene, AstraZeneca, BMS
Research Funding: Juno therapeutics, TG therapeutics, Oncternal, Pharmacyclics, LLC an AbbVie Company, Ascentage Pharma, Kite Pharma, Celgene, BeiGene, AstraZeneca
Speakers Bureau: Janssen, BeiGene, AstraZeneca, BMS
Board of Directors/Advisory Committee: AbbVie, Kite Pharma, Celgene, BeiGene, AstraZeneca, BMS
